natgillin/translations-raw huggingface dataset:
No dose adjustment is necessary for co-administered CYP3A4 substrates during treatment with Sivextro.
Nije potrebna prilagodba doze istodobno primijenjenih supstrata CYP3A4 tijekom liječenja lijekom Sivextro.
If in any doubt, contact your pharmacist for advice.
Ako niste sigurni, obratite se ljekarniku za savjet.
Two placebo-controlled crossover studies were conducted to assess the potential of 200 mg oral tedizolid phosphate at steady state to enhance pressor responses to pseudoephedrine and tyramine in healthy individuals.
Provedena su dva placebom kontrolirana ukrižena ispitivanja kako bi se procijenio potencijal 200 mg peroralnog tedizolidfosfata u stanju dinamičke ravnoteže za povećanje presorskog odgovora na pseudoefedrin i tiramin u zdravih osoba.
Following administration of a single 200 mg oral dose of tedizolid phosphate, the pharmacokinetics of tedizolid are not altered in patients with moderate (n=8) or severe (n=8) hepatic impairment (Child-Pugh Class B and C).
Nakon primjene jednokratne peroralne doze tedizolidfosfata od 200 mg, farmakokinetika tedizolida nije se promijenila u bolesnika s umjerenim (n=8) ili teškim (n=8) oštećenjem funkcije jetre (Child-Pugh stadij B i C).
• loss of sensitivity in your hands or feet (such as numbness, prickling/tingling, or sharp pains)
• gubitak osjetljivosti u šakama ili stopalima (primjerice utrnulost, peckanje/trnci ili oštri bolovi)
Table 1 Frequency of adverse reactions by System Organ Class in comparative clinical studies
Tablica 1 Učestalost nuspojava prema klasifikaciji organskih sustava u usporednim kliničkim ispitivanjima
Neuropathy (optic and peripheral) has not been reported in patients treated with tedizolid phosphate at the recommended treatment duration of 6 days.
Neuropatija (optička i periferna) nije zabilježena u bolesnika liječenih tedizolidfosfatom tijekom preporučenog trajanja liječenja od 6 dana.
Tedizolid phosphate is converted by endogenous plasma and tissue phosphatases to the microbiologically active moiety, tedizolid.
Tedizolidfosfat se pretvara endogenim fosfatazama plazme i tkiva u mikrobiološki aktivni spoj, tedizolid.
Reconstitute the contents of the vial with 4 mL water for injections, and swirl gently until the powder has dissolved entirely.
Rekonstituirajte sadržaj bočice sa 4 ml vode za injekcije i lagano okrećite dok se prašak potpuno ne otopi.
• Respiratory tract (sinuses, throat and chest) infection
• infekcija dišnih puteva (sinusi, grlo i prsište)
There is no Phase 3 clinical experience in patients with co-administration of tedizolid phosphate with serotonergic agents such as selective serotonin re-uptake inhibitors [SSRI], serotonin norepinephrine reuptake inhibitors (SNRI), tricyclic antidepressants, MAO inhibitors, triptans, and other medicines with potential adrenergic or serotonergic activity.
Nema iskustva iz kliničkih ispitivanja faze 3 u bolesnika s istodobnom primjenom tedizolidfosfata uz serotonergičke lijekove kao što su selektivni inhibitori ponovne pohrane serotonina [engl. selective serotonin re-uptake inhibitors, SSRI], inhibitori ponovne pohrane serotonina i noradrenalina (engl. serotonin norepinephrine reuptake inhibitors, SNRI), triciklički antidepresivi, inhibitori MAO, triptani i drugi lijekovi s potencijalnom adrenergičkom ili serotonergičkom aktivnošću.
In a mouse thigh infection model of S. aureus, the antibacterial activity of tedizolid was reduced in the absence of granulocytes.
U mišjem modelu infekcije bedra prouzročene bakterijom S. aureus, antibakterijska aktivnost tedizolida bila je smanjena u odsutnosti granulocita.
• sulfasalazine (used to treat inflammatory bowel diseases)
• sulfasalazin (koristi se za liječenje upalnih bolesti crijeva)
If possible, an interruption of the coadministered BCRP substrate medicinal product (such as imatinib, lapatinib, methotrexate, pitavastatin, rosuvastatin, sulfasalazine, and topotecan) should be considered during the 6 days of treatment with oral tedizolid phosphate.
Ako je moguće, potrebno je razmotriti prekid istodobne primjene lijeka koji je supstrat BCRP-a (kao što je imatinib, lapatinib, metotreksat, pitavastatin, rosuvastatin, sulfasalazin i topotekan) tijekom 6 dana liječenja peroralnom primjenom tedizolidfosfata.
Clostridioides difficile associated diarrhoea
Proljev povezan s Clostridioides difficile
What Sivextro is and what it is used for What you need to know before you take Sivextro How to take Sivextro
Što je Sivextro i za što se koristi Što morate znati prije nego počnete uzimati Sivextro Kako uzimati Sivextro
• if you are allergic to tedizolid phosphate or any of the other ingredients of this medicine (listed in section 6).
Nemojte uzimati Sivextro: • ako ste alergični na tedizolidfosfat ili neki drugi sastojak ovog lijeka (naveden u dijelu 6).
The contents of the vial should be reconstituted with 4 mL of water for injections, and be swirled gently until the powder has dissolved entirely.
Sadržaj bočice mora se rekonstituirati sa 4 ml vode za injekcije i lagano okretati dok se prašak potpuno ne otopi.
Sivextro is an antibiotic that contains the active substance tedizolid phosphate.
Sivextro je antibiotik koji sadrži djelatnu tvar tedizolidfosfat.
Do not use this medicine after the expiry date which is stated on the vial label after “EXP”.
Ovaj lijek se ne smije upotrijebiti nakon isteka roka valjanosti navedenog na bočici iza oznake „EXP“.
The safety and efficacy of tedizolid phosphate when administered for periods longer than 6 days have not been established.
Sigurnost i djelotvornost tedizolidfosfata kada se primjenjuje duže od 6 dana nisu ustanovljene.
• Dry mouth, constipation, indigestion, pain/discomfort in the belly (abdomen), retching, dry heaving, bright red blood in the stool
• suha usta, zatvor, probavne tegobe, bol/nelagoda u trbuhu (abdomenu), dizanje želuca, svijetlo crvena krv u stolici
Clostridioides difficile associated diarrhoea (CDAD) has been reported for tedizolid phosphate (see section 4.8).
Clostridioides difficile associated diarrhoea, CDAD) (vidjeti dio 4.8).
• Sleepiness, abnormal sleep pattern, difficulty sleeping, nightmares (unpleasant/disturbing dreams)
• pospanost, poremećen obrazac spavanja, poteškoće sa spavanjem, noćne more
Blood and lymphatic system disorders
Poremećaji krvi i limfnog sustava limfadenopatija
In Phase 3 studies, subjects taking serotonergic agents including antidepressants such as selective serotonin reuptake inhibitors (SSRIs), tricyclic antidepressants, and serotonin 5-hydroxytryptamine (5-HT1) receptor agonists (triptans), meperidine, or buspirone were excluded.
U ispitivanjima faze 3 isključeni su ispitanici koji uzimaju serotonergičke lijekove uključujući antidepresive, primjerice selektivne inhibitore ponovne pohrane serotonina (engl. selective serotonin reuptake inhibitors, SSRI), tricikličke antidepresive i agoniste receptora serotonina 5-hidroksitriptamina (5-HT1) (triptane), meperidin ili buspiron.
• Swollen or enlarged lymph nodes
• otečeni ili povećani limfni čvorovi
Following administration of a single 200 mg IV dose of tedizolid phosphate to 8 subjects with severe renal impairment defined as eGFR <30 mL/min, the Cmax was basically unchanged and AUC0-∞ was changed by less than 10% compared to 8 matched healthy subject controls.
Nakon primjene jednokratne intravenske doze tedizolidfosfata od 200 mg u 8 ispitanika s teškim oštećenjem funkcije bubrega definiranim kao eGFR <30 ml/min, Cmax je bio u načelu neizmijenjen, a AUC0-∞ je bio izmijenjen za manje od 10% u usporedbi s 8 odgovarajućih zdravih kontrolnih ispitanika.
Lactic acidosis has not been reported in patients treated with tedizolid phosphate at the recommended treatment duration of 6 days.
Laktacidoza nije zabilježena u bolesnika liječenih tedizolidfosfatom tijekom preporučenog trajanja liječenja od 6 dana.
These effects occurred at plasma tedizolid exposure levels (AUC) ≥3-fold greater than the expected human plasma exposure associated with the therapeutic dose.
Ti su se učinci javili pri razinama izloženosti tedizolidu u plazmi (AUC) ≥3 puta većim od očekivane izloženosti u ljudskoj plazmi povezanoj s terapijskom dozom.
Oral and intravenous tedizolid phosphate is a prodrug that is rapidly converted by phosphatases to tedizolid, the microbiologically active moiety.
Peroralni i intravenski tedizolidfosfat je predlijek koji fosfataze brzo pretvaraju u tedizolid, mikrobiološki aktivni spoj.
The mean steady state volume of distribution of tedizolid in healthy adults (n=8) following a single intravenous dose of tedizolid phosphate 200 mg ranged from 67 to 80 L.
Srednji volumen distribucije tedizolida u stanju dinamičke ravnoteže u zdravih odraslih osoba (n=8) nakon jedne intravenske doze tedizolidfosfata od 200 mg varirao je od 67 do 80 l.
EU/1/15/991/002 1 vial EU/1/15/991/003 6 vials
EU/1/15/991/002 1 bočica EU/1/15/991/003 6 bočica
These effects showed evidence of reversibility and occurred at plasma tedizolid exposure levels (AUC) ≥6-fold greater than the plasma exposure associated with the human therapeutic dose.
Ti su se učinci pokazali reverzibilnima i javili su se pri razinama izloženosti tedizolidu u plazmi (AUC) ≥6 puta većim od izloženosti u plazmi povezanoj s ljudskom terapijskom dozom.
Table 1 Frequency of adverse reactions by System Organ Class in pooled Phase 3 comparative clinical studies
Tablica 1 Učestalost nuspojava prema klasifikaciji organskih sustava u udruženim usporednim kliničkim ispitivanjima faze 3
The following adverse reactions have been identified in two comparative pivotal Phase 3 studies and one post-authorisation study with Sivextro (Table 1).
Sljedeće su nuspojave zabilježene u dvama usporednim pivotalnim ispitivanjima faze 3 i jednom ispitivanju nakon dobivanja odobrenja za stavljanje lijeka u promet s lijekom Sivextro (Tablica 1).
It must be administered as an intravenous infusion only.
Smije se primjenjivati isključivo intravenskom infuzijom.
Foetal developmental effects occurring in mice in the absence of maternal toxicity included reduced foetal weights and an increased incidence of costal cartilage fusion (an exacerbation of the normal genetic predisposition to sternal variations in the CD-1 strain of mice) at the high dose of 25 mg/kg/day (4-fold the estimated human exposure level based on AUCs).
Učinci na fetalni razvoj koji se pojavljuju u miševa u odsustvu toksičnosti za majku uključivali su smanjenu fetalnu težinu i povećanu incidenciju fuzije rebrene hrskavice (pogoršanje normalne genetske predispozicije za sternalne promjene u mišjem soju CD-1) pri visokoj dozi od 25 mg/kg/dan (4 puta viša od procijenjene ljudske razine izloženosti na temelju AUC-a).
The reconstituted solution will be withdrawn from the vial and added to an infusion bag of 0.9% sodium chloride in the hospital.
Rekonstituiranu otopinu treba izvući iz bočice i dodati u infuzijsku vrećicu 0,9%-tne otopine natrijevog klorida u bolnici.
Tedizolid was positive in an in vitro CHL cell chromosomal aberration assay, but negative for genotoxicity in other in vitro assays (Ames, mouse lymphoma mutagenicity) and in vivo in a mouse bone marrow micronucleus assay.
Tedizolid je bio pozitivan u in vitro testu kromosomske aberacije u stanicama CHL, ali je bio negativan na genotoksičnost u drugim in vitro testovima (Ames, mutagenost mišjeg limfoma) i in vivo u mikronukleusnom testu na mišjoj koštanoj srži.
The reconstituted solution must be administered as an intravenous infusion only.
Rekonstituirana otopina smije se primjenjivati isključivo intravenskom infuzijom.
It is available in 6 × 1 tablets in perforated unit-dose blisters.
Lijek je dostupan u perforiranim blisterima s jediničnim dozama sa 6 × 1 tableta.
It is not known if Sivextro passes into breast milk in humans.
Nije poznato izlučuje li se Sivextro u majčino mlijeko.
Contact your doctor, pharmacist or nearest hospital casualty department as soon as possible if you have taken more tablets than you should, and take your medicine with you.
Ako uzmete više lijeka Sivextro nego što ste trebali Obratite se čim prije liječniku, ljekarniku ili hitnoj službi najbliže bolnice ako ste uzeli više tableta nego što ste trebali, i ponesite lijek sa sobom.
In rats, decreased foetal weights and increased skeletal variations including reduced ossification of the sternabrae, vertebrae, and skull were observed at the high dose of 15 mg/kg/day (6-fold the estimated human exposure based on AUCs) and were associated with maternal toxicity (reduced maternal body weights).
U štakora, smanjene fetalne težine i povećane koštane promjene, uključujući smanjenu osifikaciju sternebrae, kralježaka i lubanje, opažene su pri visokoj dozi od 15 mg/kg/dan (6 puta viša od procijenjene ljudske izloženosti na temelju AUC-a) i bile su povezane s toksičnosti za majku (smanjene tjelesne težine majke).
Peel, then push
Odvojite foliju, zatim protisnite
Lactic acidosis has been reported with the use of another member of the oxazolidinone class.
Laktacidoza je prijavljena prilikom primjene drugog lijeka iz skupine oksazolidinona.
• The active substance is tedizolid phosphate.
• Djelatna tvar je tedizolidfosfat.
The film coat of the tablet contains polyvinyl alcohol, titanium dioxide (E171), macrogol, talc and yellow iron oxide (E172).
Ovojnica tablete poli(vinilni alkohol) titanijev dioksid (E171) makrogol talk željezov oksid, žuti (E172)
Sivextro is incompatible with any solutions containing divalent cations (e.g., Ca
Sivextro je inkompatibilan sa svim otopinama koje sadrže dvovalentne katione (npr. Ca
6 × 1 tablets in aluminum/Polyethylene Terephthalate (PET)/Paper foil and polyvinyl chloride (PVC)/polyvinylidene chloride (PVdC) clear film perforated child-resistant unit-dose blisters.
6 × 1 tableta u perforiranim blisterima sigurnima za djecu s jediničnim dozama od folije od aluminija/polietilentereftaleata (PET)/papira i prozirnog filma od polivinilklorida (PVC)/polivinilidenklorida (PVdC).
The no observed adverse effect levels (NOAELs) for foetal toxicity in mice (5 mg/kg/day) as well as maternal and foetal toxicity in rats (2.5 mg/kg/day) were associated with tedizolid plasma area under the curve (AUC) values approximately equivalent to the tedizolid AUC value associated with the oral human therapeutic dose.
Razine izloženosti pri kojima nisu opaženi štetni učinci (engl. no observed adverse effect level, NOAEL) za fetalnu toksičnost u miševa (5 mg/kg/dan) niti toksičnost za majku te fetalnu toksičnost u štakora (2,5 mg/kg/dan) bile su povezane s vrijednostima površine ispod krivulje (AUC) tedizolida u plazmi koje su približno jednake vrijednosti AUC-a tedizolida povezanoj s peroralnom ljudskom terapijskom dozom.
The pharmacokinetics of tedizolid were evaluated in adolescent subjects (12 to 17 years; n=20) following administration of a single oral or IV dose of tedizolid phosphate 200 mg.
Farmakokinetika tedizolida procijenjena je u ispitanika u adolescentnoj dobi (od 12 do 17 godina; n=20) nakon primjene jednokratne peroralne ili intravenske doze tedizolidfosfata od 200 mg.
Medicinal products inhibiting peristalsis are contraindicated in this situation.
U toj je situaciji kontraindicirana primjena lijekova koji inhibiraju crijevnu peristaltiku.
Peak plasma tedizolid concentrations are achieved within approximately 3 hours after dosing after oral administration of tedizolid phosphate under fasted conditions.
Vršne koncentracije tedizolida u plazmi dostižu se približno 3 sata nakon doze tedizolidfosfata primijenjene peroralno natašte.
What Sivextro looks like and contents of the pack Sivextro is a white to off-white powder for concentrate for solution for infusion in a glass vial.
Sivextro je bijeli do bjelkasti prašak za koncentrat za otopinu za infuziju u staklenoj bočici.
Therefore, orally administered tedizolid phosphate can result in inhibition of BCRP at the intestinal level.
Stoga, peroralna primjena tedizolidfosfata može rezultirati inhibicijom BCRP-a na razini crijeva.
Patients should not take a double dose to compensate for a missed dose.
Bolesnik ne smije uzeti dvostruku dozu kako bi nadoknadio propuštenu dozu.
Aseptic technique must be followed in preparing the infusion solution.
Za pripremu infuzijske otopine mora se koristiti aseptička tehnika.
Tedizolid is bacteriostatic against enterococci, staphylococci, and streptococci in vitro.
Tedizolid ima bakteriostatsko djelovanje na enterokoke, stafilokoke i streptokoke in vitro.
Monoamine oxidase inhibition
Inhibicija monoaminoksidaze
• Itching (including itching due to allergic reaction), hair loss, acne, red and/or itchy rash or hives,
• svrbež (uključujući svrbež zbog alergijske reakcije), gubitak kose, akne, crveni osip i/ili osip praćen svrbežom ili koprivnjača, pretjerano znojenje
A double dose should not be given to compensate for a missed dose.
Ne smije mu se dati dvostruka doza kako bi se nadoknadila propuštena doza.
Sivextro contains sodium
Sivextro sadrži natrij
See Other medicines and Sivextro for examples.
Za primjere pogledajte dio Drugi lijekovi i Sivextro.
What you need to know before you take Sivextro
Što morate znati prije nego počnete uzimati Sivextro
In ABSSSI, the types of infections treated were confined to cellulitis/erysipelas or major cutaneous abscesses, and wound infections only.
U ispitivanju akutnih bakterijskih infekcija kože i kožnih struktura, vrste liječenih infekcija bile su ograničene samo na celulitis/erizipel ili veće kožne apscese i infekcije rana.
Yellow iron oxide (E172)
makrogol, talk i žuti željezov oksid (E172).
Tedizolid phosphate was negative for genotoxicity in all in vitro assays (bacterial reverse mutation [Ames], Chinese hamster lung [CHL] cell chromosomal aberration) and in all in vivo tests (mouse bone marrow micronucleus, rat liver unscheduled DNA synthesis).
Tedizolidfosfat nije pokazao genotoksičnost u svim in vitro testovima (test reverzne mutacije bakterija [Ames], test kromosomske aberacije u stanicama pluća kineskog hrčka [CHL]) i u svim in vivo testovima (mikronukleusni test na mišjoj koštanoj srži, neplanirana sinteza DNK na stanicama jetre štakora).
Tedizolid, generated from tedizolid phosphate after metabolic activation (in vitro and in vivo), was also tested for genotoxicity.
Također je ispitana genotoksičnost tedizolida, koji se stvara iz tedizolidfosfata nakon metaboličke aktivacije (in vitro i in vivo).
Aseptic technique must be followed when preparing the infusion solution.
Tijekom pripreme infuzijske otopine mora se koristiti aseptička tehnika.
A second resistance mechanism is encoded by a plasmid-borne and transposon associated chloramphenicol-florfenicol resistance (cfr) gene, conferring resistance in staphylococci and enterococci to oxazolidinones, phenicols, lincosamides, pleuromutilins, streptogramin A and 16membered macrolides.
Drugi mehanizam rezistencije je kodiran genom za rezistenciju na kloramfenikol-florfenikol (cfr) koji se nalazi na plazmidu, a povezan je s transpozonom, što dovodi do rezistencije na oksazolidinone, fenikole, linkozamide, pleuromutiline, streptogramin A i 16-člane makrolide u stafilokoka i enterokoka.
Important: Please refer to the Summary of Product Characteristics (SmPC) before prescribing.
Važno: Pogledajte Sažetak opisa svojstava lijeka prije propisivanja.
Repeated oral and intravenous dosing of tedizolid phosphate in rats in 1-month and 3-month toxicology studies produced dose- and time-dependent bone marrow hypocellularity (myeloid, erythroid, and megakaryocyte), with associated reduction in circulating RBCs, WBCs, and platelets.
Ponovljeno peroralno i intravensko doziranje tedizolidfosfata u štakora u jednomjesečnim i tromjesečnim ispitivanjima toksičnosti prouzročilo je hipocelularnost koštane srži (mijeloidnu, eritroidnu i megakariocitnu) ovisnu o dozi i vremenu, s povezanim smanjenjem cirkulirajućih crvenih krvnih stanica, bijelih krvnih stanica i trombocita.
If you forget to take your medicine, take the dose as soon as possible anytime up to 8 hours prior to the next scheduled dose.
Zaboravite li uzeti lijek, uzmite dozu što prije, u bilo koje vrijeme najkasnije do 8 sati prije sljedeće planirane doze.
How to take Sivextro
Kako uzimati Sivextro
• Acid reflux disease (heartburn, pain or difficulty swallowing), flatulence/passing wind
• refluksna bolest uzrokovana povratom kiseline (žgaravica, bol ili otežano gutanje), vjetrovi
Multiple sulfotransferase (SULT) isoforms (SULT1A1, SULT1A2, and SULT2A1) were identified in vitro that are capable of conjugating tedizolid which suggests that no single isozyme is critical to the clearance of tedizolid.
In vitro su bili utvrđeni višestruki izooblici sulfotransferaze (SULT1A1, SULT1A2 i SULT2A1) koji mogu konjugirati tedizolid, što ukazuje da nijedan od tih enzima nije sam ključan za klirens tedizolida.
Adverse reactions are classified by preferred term and System Organ Class, and by frequency.
Nuspojave su klasificirane prema preporučenom pojmu i klasifikaciji organskih sustava te prema učestalosti.
A clinical study comparing the single dose (2 mg) pharmacokinetics of midazolam (CYP3A4 substrate) alone or in combination with tedizolid phosphate (once-daily 200 mg oral dose for 10 days), demonstrated no clinically meaningful difference in midazolam Cmax or AUC.
Kliničko ispitivanje u kojem se usporedila farmakokinetika jedne doze (2 mg) midazolama (supstrata CYP3A4) primijenjenog samog ili u kombinaciji s tedizolidfosfatom (oralna doza od 200 mg jedanput na dan tijekom 10 dana) pokazalo je da nema klinički značajne razlike u Cmax ili AUC midazolama.
Certain side effects have been observed with another member of the oxazolidinone class when administered over a duration exceeding that recommended for Sivextro.
Određene nuspojave primijećene su kod liječenja drugim lijekom iz skupine oksazolidinona kada je trajanje primjene bilo duže od onog preporučenog za Sivextro.
Drug metabolizing enzymes
Enzimi koji metaboliziraju lijek
• Abnormal smelling urine, abnormal blood tests
• neuobičajen miris mokraće, odstupanja u rezultatima krvnih pretraga
What you need to know before you are given Sivextro
Što morate znati prije nego počnete dobivati Sivextro
Irritability Pyrexia
bol na mjestu infuzije razdražljivost pireksija
Type I (10 ml) clear borosilicate tubing glass vial with a siliconised grey chlorobutyl rubber stopper.
I od 10 ml sa sivim čepom od silikonizirane klorobutilne gume.
Recommended dose and duration The recommended dosage is 200 mg once daily for 6 days.
Preporučena doza je 200 mg jedanput na dan tijekom 6 dana.
Sivextro 200 mg powder for concentrate for solution for infusion
Sivextro 200 mg prašak za koncentrat za otopinu za infuziju
Sivextro 200 mg film-coated tablets
Sivextro 200 mg filmom obložene tablete
Alternative therapies should be considered when treating patients with neutropenia and ABSSSI (see section 5.1).
Potrebno je razmotriti druge terapije prilikom liječenja bolesnika s neutropenijom i akutnom bakterijskom infekcijom kože i kožnih struktura (vidjeti dio 5.1).
Sodium hydroxide (for pH adjustment) Hydrochloric acid (for pH adjustment)
6.1 Popis pomoćnih tvari manitol natrijev hidroksid (za podešavanje pH) kloridna kiselina (za podešavanje pH)
If less than 8 hours remains before the next dose, then wait until the next scheduled dose.
Ako je do sljedeće doze ostalo manje od 8 sati, tada pričekajte do sljedeće planirane doze.
If a dose is missed, it should be taken as soon as possible anytime up to 8 hours prior to the next scheduled dose.
Propusti li se doza lijeka, treba je uzeti što prije, u bilo koje vrijeme do najkasnije 8 sati prije sljedeće planirane doze.
These events have been observed with another member of the oxazolidinone class when administered over a duration exceeding that recommended for tedizolid phosphate.
Ti su događaji primijećeni kod liječenja drugim lijekom iz skupine oksazolidinona u trajanju dužem od preporučenog za tedizolidfosfat.
After reconstitution each ml contains 50 mg tedizolid phosphate.
Nakon rekonstitucije, jedan ml sadrži 50 mg tedizolidfosfata.